Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye test could spot Alzheimer's early, study hints

NCT ID NCT04794634

Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether thinning of the retina (the back part of the eye) can be a sign of Alzheimer's disease. Researchers compared eye scans from 55 people with Alzheimer's, Lewy body disease, and healthy volunteers. The goal was to see if measuring retinal layers could help doctors diagnose Alzheimer's more easily and cheaply.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

55 people

The number who actually took part.

Started

Jan 2021

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients having a consultation in the Research and Resources Memory Center of Amiens (RRMC) , * patients registered in the Alzheimer National Bank and having an Alzheimer Disease based on NIA-AA (McKahnn2011)and IWG2 (Dubois et al, 2014) criteria or, having a Lewy body disease based on revised criteria of McKeith et al 2020 * patients having a complete neuropsychological evaluation including a visual inspection time. * patients having a MMSE ≥ 18/30 so as to ensure a good homogeneity of the group and to have an adequate ocular exam's quality. * patients having an available MRI in the CHU's database including a 3DT1 sequence * patients having a visual acuity better than 5/10, spherical refraction of +/- 5D, an astigmatism \< 3D and an applanation IOP \<22mmHg Exclusion Criteria: * Any other neurocognitive disorder * Any other optical neuropathy including glaucoma * All kind of retinal disease (diabetic retinopathy, age-related macular degeneration…) * Diabetes mellitus * Uncontrolled hypertension blood pressure * Any ophthalmological conditions interfering with a good ocular examination or OCT quality (cataract, corneal opacity..) * Severe dementia preventing a good ophthalmological examination * Not consenting patient * Patient with guardianship or curatorship having symptoms preventing a good ophthalmological examination (agitation, unstable ocular fixation)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Lewy body dementia Lewy Body Disease retinal edema retinal nerve fiber layer disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease Cortical atrophy Lewy body disease Optical coherence tomography Optical coherence tomography angiography RETINA Retinal nerve fibres layer Retinal thickening

Contacts and locations

Locations

  • CHU Amiens

    Amiens, 80480, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.